Page last updated: 2024-08-24

fluorodeoxyglucose f18 and me-344

fluorodeoxyglucose f18 has been researched along with me-344 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Apala, JV; Caleiras, E; Cortés, J; Cortés-Salgado, A; Gasol Cudos, A; Gion, M; Guerra, J; Lopez-Alonso, A; Malón, D; Manso, L; Morales, S; Mouron, S; Mulero, F; Muñoz, M; Quintela-Fandino, M; Salla Fortuny, J	1

Trials

1 trial(s) available for fluorodeoxyglucose f18 and me-344

Article	Year
Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 01-01, Volume: 26, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Isoflavones; Ki-67 Antigen; Middle Aged; Mitochondria; Neoplasm Staging; Patient Safety; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Succinate Dehydrogenase; Treatment Outcome	2020

Article

Year

Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 01-01, Volume: 26, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Isoflavones; Ki-67 Antigen; Middle Aged; Mitochondria; Neoplasm Staging; Patient Safety; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Succinate Dehydrogenase; Treatment Outcome

2020